Baseline Characteristics of Study Participants
From January 2017 through November 2020, 2055 patients were enrolled at 21 study centers. Four patients were lost to follow-up (2 patients in the rivaroxaban 2.5 group and 2 patients in the rivaroxaban 5 mg group), 5 patients decided to withdraw from the study after randomization for individual reasons before receiving rivaroxaban or enoxaparin, and 2046 patients (mean [SD] age 65.8 [8.2] years, 1443 [70.5%] male) were randomized to enoxaparin (680 patients), rivaroxaban 2.5 mg (683 patients), or rivaroxaban 5 mg (683 patients) and finished the 6-month follow-up (